University of Utah
Salt Lake City, Utah, 84132, United States
NCT Number: NCT02737345
1. Further characterize the incidence of hyperfibrinolysis in cirrhotics 2. Correlate hyperfibrinolysis with
1. hepatitis C 2. alcoholic liver disease 3. the subset of a&b with renal failure with and without dialysis 3. Better describe the hyperfibrinolytic ROTEM profile in cirrhotics
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Salt Lake City, Utah, 84132, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Within 60 minutes of sample run time
The percentage of patients who exhibit fibrinolysis, defined as a decrease in maximum clot firmness <15% within 60 minutes of sample run time.
Scott Allen
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07417163
Cirrhosis, Dyssomnias
Boston, Massachusetts, United States
View Trial DetailsNCT07703540
Cirrhosis, Digestive System Diseases
Münster, North Rhine-Westphalia, Germany
View Trial DetailsNCT06062108
Acute Pain, Chronic Pain
Draguignan, Var, France
View Trial DetailsNCT03849235
Cirrhosis, Digestive System Diseases
Hvidovre, Capital Region Denmark, Denmark
View Trial Details